Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Helus Pharma Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HELP
Nasdaq
2834
www.helus.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Helus Pharma Inc.
Helus Pharma (HLP) Stock Fair Value Rises After HLP003 Phase 3 Analyst Revisions
- Nov 18th, 2026 1:12 am
HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data
- Nov 16th, 2026 1:52 pm
Why Is HELP Stock Rising Today?
- Nov 16th, 2026 6:50 am
Helus Pharma Shares Fall 21% Despite Phase 3 HLP003 Trial Meeting Primary Endpoint
- Nov 16th, 2026 6:34 am
Helus Pharma stock tumbles 21% despite positive trial results
- Nov 16th, 2026 6:07 am
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
- Nov 16th, 2026 5:00 am
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
- Nov 16th, 2026 4:00 am
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
- Nov 15th, 2026 10:00 am
Helus Pharma (HELP) Could Be 78% Below Fair Value After Conference Spotlight
- Nov 10th, 2026 8:16 pm
Is Helus Pharma (HELP) Trading At A Premium To Book Value?
- Nov 10th, 2026 7:16 pm
Cybin Expects Key Phase III Depression Trial Results This Quarter
- Nov 9th, 2026 10:14 pm
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
- Nov 3rd, 2026 5:30 am
Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
- Oct 27th, 2026 6:00 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Oct 26th, 2026 4:02 pm
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
- Oct 21st, 2026 2:10 pm
Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances
- Oct 21st, 2026 12:04 pm
Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?
- Oct 20th, 2026 9:00 am
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
- Oct 15th, 2026 5:30 am
Helus Pharma to Host Investor Presentation on October 21, 2026
- Oct 8th, 2026 5:30 am
Scroll